Trials / Completed
CompletedNCT00320060
Effect of Pyridorin in Patients With Diabetic Nephropathy
A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, 24-Week Study to Evaluate the Safety and Tolerability of Pyridorin (Pyridoxamine Dihydrochloride) in Patients With Diabetic Nephropathy Associated With Type 1 or Type 2 Diabetes
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 128 (planned)
- Sponsor
- BioStratum · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of the study is to evaluate the safety and tolerability of Pyridorin (pyridoxamine dihydrochloride) 50 mg given orally twice daily in patients with diabetic kidney disease.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pyridorin (pyridoxamine dihydrochloride) |
Timeline
- Start date
- 2001-10-01
- Completion
- 2003-01-01
- First posted
- 2006-04-27
- Last updated
- 2006-04-27
Source: ClinicalTrials.gov record NCT00320060. Inclusion in this directory is not an endorsement.